Beer TM - Search Results

1

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.

Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, Bailey S, Latour E, Newby TA, Moran AE, Beer TM. Graff JN, et al. Among authors: beer tm. Front Oncol. 2020 Aug 7;10:1381. doi: 10.3389/fonc.2020.01381. eCollection 2020. Front Oncol. 2020. PMID: 32850444 Free PMC article.

2

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

Beer TM, Pierce WC, Lowe BA, Henner WD. Beer TM, et al. Ann Oncol. 2001 Sep;12(9):1273-9. doi: 10.1023/a:1012258723075. Ann Oncol. 2001. PMID: 11697840 Free article. Clinical Trial.

3

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.

Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Beer TM, et al. J Clin Oncol. 2003 Jan 1;21(1):123-8. doi: 10.1200/jco.2003.05.117. J Clin Oncol. 2003. PMID: 12506180 Clinical Trial.

4

Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen.

Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, Garzotto M. Panagiotou I, et al. Among authors: beer tm. Oncology. 2004;67(3-4):194-202. doi: 10.1159/000081317. Oncology. 2004. PMID: 15557778

5

High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer.

Beer TM, Garzotto M, Katovic NM. Beer TM, et al. Am J Clin Oncol. 2004 Oct;27(5):535-41. doi: 10.1097/01.coc.0000136020.27904.9c. Am J Clin Oncol. 2004. PMID: 15596926 Clinical Trial.

6

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.

Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Graff JN, et al. Among authors: beer tm. J Urol. 2007 Apr;177(4):1307-12. doi: 10.1016/j.juro.2006.11.054. J Urol. 2007. PMID: 17382720 Clinical Trial.

7

Optimal timing of chemotherapy in androgen independent prostate cancer.

Schnadig ID, Beer TM. Schnadig ID, et al. Among authors: beer tm. Urol Oncol. 2009 Jan-Feb;27(1):97-100. doi: 10.1016/j.urolonc.2008.04.004. Urol Oncol. 2009. PMID: 19111808 Review.

8

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM. Prins RC, et al. Among authors: beer tm. Urol Oncol. 2012 Jan-Feb;30(1):33-7. doi: 10.1016/j.urolonc.2009.11.012. Epub 2010 Mar 6. Urol Oncol. 2012. PMID: 20207556 Free PMC article.

9

Toward predictors of survival in castration-resistant prostate cancer.

Graff JN, Beer TM. Graff JN, et al. Among authors: beer tm. Cancer. 2011 Sep 1;117(17):3882-4. doi: 10.1002/cncr.25986. Epub 2011 Mar 9. Cancer. 2011. PMID: 21391212 Free article. No abstract available.

10

Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.

Graff JN, Drake CG, Beer TM. Graff JN, et al. Among authors: beer tm. Urology. 2013 Feb;81(2):381-3. doi: 10.1016/j.urology.2012.10.044. Urology. 2013. PMID: 23374810 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters